Singapore-listed Tianjin Zhong Xin Pharmaceutical Group has obtained approval from the Singapore Exchange (SGX) to waive the group's obligation to hold its annual general meetings in Singapore.

The group, which is incorporated in mainland China and listed in both Singapore and China, had applied to the SGX to allow it to continue to hold its general meetings in China instead of Singapore.

It said its shareholders in China made up more than 95 per cent of its total shareholders, and 73 per cent of its total voting rights. Out of the group's 45,717 shareholders, 43,632 are based in China and 2,085 are in Singapore.

Tianjin Zhong Xin said it would make arrangements - such as video conferencing or webcasts - to enable Singapore-based shareholders to follow the proceedings during its general meetings in China.